Frazier Lifesciences Acquisition Corporation Stock

FLAC

KYG3710A1058

Chart Frazier Lifesciences Acquisition Corporation

Duration

Period

Style

Dynamic Chart

Latest news about Frazier Lifesciences Acquisition Corporation

Frazier Lifesciences Acquisition Corporation Announces Executive Changes	22-11-23	CI
Frazier Lifesciences Acquisition Corporation(NasdaqCM:FLAC) dropped from NASDAQ Composite Index	22-11-22	CI
NewAmsterdam Pharma B.V. completed the acquisition of Frazier Lifesciences Acquisition Corporation from a group of shareholders in a reverse merger transaction.	22-11-21	CI
Frazier Lifesciences Shareholders Approve Merger With NewAmsterdam Pharma Holding	22-11-15	MT
Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
NewAmsterdam Pharma to Go Public in Deal With Frazier Lifesciences SPAC	22-07-25	MT
NewAmsterdam Pharma B.V. entered into a definitive business combination agreement to acquire Frazier Lifesciences Acquisition Corporation from a group of shareholders for approximately $490 million.	22-07-24	CI
Frazier Lifesciences Acquisition Negotiates Business Combination With NewAmsterdam Pharma	22-07-20	MT
Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-25	CI
Frazier Lifesciences Acquisition Corporation Auditor Raises 'Going Concern' Doubt	22-03-24	CI
Certain Class B Ordinary Shares of Frazier Lifesciences Acquisition Corporation are subject to a Lock-Up Agreement Ending on 6-JUN-2021.	21-06-05	CI
Frazier Lifesciences Acquisition Corp.(NasdaqCM:FLAC) added to NASDAQ Composite Index	21-02-09	CI
Frazier Lifesciences Acquisition Corp. announced that it has received $5.01 million in funding from Frazier Lifesciences Sponsor LLC	20-12-10	CI

More news

Press releases Frazier Lifesciences Acquisition Corporation

NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib	22-11-24	AQ
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease Patients	22-11-23	AQ
Frazier Lifesciences Acquisition Corporation shareholders approve business combination with NewAmsterdam Pharma Holding B.V	22-11-16	AQ
FRAZIER LIFESCIENCES ACQUISITION CORP : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-11-15	AQ
Frazier Lifesciences Acquisition Corporation Shareholders Approve Business Combination with NewAmsterdam Pharma Holding B.V.	22-11-15	BU

More press releases

Frazier Lifesciences Acquisition Corporation is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. It intends to identify opportunities in the biotechnology sector. It has conducted no operations and has generated no revenues.

Sector

More about the company